Biomarker analysis for Vectibix in CRC published in NEJM
A biomarker analysis of Vectibix (panitumumab), from Amgen, in combination with FOLFOX for first-line treatment of patients with metastatic Colorectal Cancer (mCRC) has been published in the New England Journal of Medicine. The analysis found that RAS mutations, beyond the known KRAS exon 2 mutations, predict lack of response to Vectibix in combination with FOLFOX. By more precisely narrowing the pool of patients treated with Vectibix plus FOLFOX to those with wild-type RAS, greater improvements in overall survival (OS) and progression-free survival (PFS) were observed.
Previous data found that OS was improved by 4.4 months in patients with wild-type KRAS. By further narrowing to patients with wild-type RAS, an improvement in OS of 5.8 months was observed. See: "Panitumumab�FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer." Jean-Yves Douillard et al. NEJM 369:1023-1034 September 12, 2013 doi: 10.1056/NEJMoa1305275
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.